Serum tau protein elevation in migraine: a cross-sectional case–control study
Abstract Background Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases and can be influenced by neuropeptides such as CGRP, a key neurotransmitter in migraine. Here, we report serum concentrations of total...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-023-01663-5 |
| _version_ | 1797557594952302592 |
|---|---|
| author | Lucas Hendrik Overeem Bianca Raffaelli Robert Fleischmann Marie Süße Antje Vogelgesang Aleksandra Maleska Maceski Athina Papadopoulou Klemens Ruprecht Wendy Su Mirja Koch Anke Siebert Michal Arkuszewski Nadia Tenenbaum Jens Kuhle Uwe Reuter |
| author_facet | Lucas Hendrik Overeem Bianca Raffaelli Robert Fleischmann Marie Süße Antje Vogelgesang Aleksandra Maleska Maceski Athina Papadopoulou Klemens Ruprecht Wendy Su Mirja Koch Anke Siebert Michal Arkuszewski Nadia Tenenbaum Jens Kuhle Uwe Reuter |
| author_sort | Lucas Hendrik Overeem |
| collection | DOAJ |
| description | Abstract Background Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases and can be influenced by neuropeptides such as CGRP, a key neurotransmitter in migraine. Here, we report serum concentrations of total-tau protein in migraine patients and healthy controls. Methods In this cross-sectional study, interictal blood samples from n = 92 patients with episodic migraine (EM), n = 93 patients with chronic migraine (CM), and n = 42 healthy matched controls (HC) were studied. We assessed serum total-tau protein (t-tau) and for comparison neurofilament light chain protein (NfL), glial fibrillary acidic protein (GFAP), and ubiquitin carboxy-terminal hydrolase L (UCH-L1) concentrations using the Neurology 4-plex kit, on a single molecule array HD-X Analyzer (Quanterix Corp Lexington, MA). Matched serum/cerebrospinal fluid (CSF) samples were used for post-hoc evaluations of a central nervous system (CNS) source of relevant findings. We applied non-parametric tests to compare groups and assess correlations. Results Serum t-tau concentrations were elevated in EM [0.320 (0.204 to 0.466) pg/mL] and CM [0.304 (0.158 to 0.406) pg/mL] patients compared to HC [0.200 (0.114 to 0.288) pg/mL] (p = 0.002 vs. EM; p = 0.025 vs. CM). EM with aura [0.291 (0.184 to 0.486 pg/mL); p = 0.013] and EM without aura [0.332 (0.234 to 0.449) pg/mL; p = 0.008] patients had higher t-tau levels than HC but did not differ between each other. Subgroup analysis of CM with/without preventive treatment revealed elevated t-tau levels compared to HC only in the non-prevention group [0.322 (0.181 to 0.463) pg/mL; p = 0.009]. T-tau was elevated in serum (p = 0.028) but not in cerebrospinal fluid (p = 0.760). In contrast to t-tau, all proteins associated with cell damage (NfL, GFAP, and UCH-L1), did not differ between groups. Discussion Migraine is associated with t-tau elevation in serum but not in the CSF. Our clinical study identifies t-tau as a new target for migraine research. |
| first_indexed | 2024-03-10T17:19:03Z |
| format | Article |
| id | doaj.art-324d4772a1664655906ce353a7b96de0 |
| institution | Directory Open Access Journal |
| issn | 1129-2377 |
| language | English |
| last_indexed | 2024-03-10T17:19:03Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | The Journal of Headache and Pain |
| spelling | doaj.art-324d4772a1664655906ce353a7b96de02023-11-20T10:22:54ZengBMCThe Journal of Headache and Pain1129-23772023-09-0124111110.1186/s10194-023-01663-5Serum tau protein elevation in migraine: a cross-sectional case–control studyLucas Hendrik Overeem0Bianca Raffaelli1Robert Fleischmann2Marie Süße3Antje Vogelgesang4Aleksandra Maleska Maceski5Athina Papadopoulou6Klemens Ruprecht7Wendy Su8Mirja Koch9Anke Siebert10Michal Arkuszewski11Nadia Tenenbaum12Jens Kuhle13Uwe Reuter14Department of Neurology With Experimental Neurology, Charité – Universitätsmedizin BerlinDepartment of Neurology With Experimental Neurology, Charité – Universitätsmedizin BerlinDepartment of Neurology, Universitätsmedizin GreifswaldDepartment of Neurology, Universitätsmedizin GreifswaldDepartment of Neurology, Universitätsmedizin GreifswaldDepartment of Neurology, University Hospital and University of BaselDepartment of Neurology, University Hospital and University of BaselDepartment of Neurology With Experimental Neurology, Charité – Universitätsmedizin BerlinNovartis Pharma AGNovartis Pharma AGDepartment of Neurology With Experimental Neurology, Charité – Universitätsmedizin BerlinNovartis Pharma AGEMD Serono Research and Development InstituteDepartment of Neurology, University Hospital and University of BaselDepartment of Neurology With Experimental Neurology, Charité – Universitätsmedizin BerlinAbstract Background Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases and can be influenced by neuropeptides such as CGRP, a key neurotransmitter in migraine. Here, we report serum concentrations of total-tau protein in migraine patients and healthy controls. Methods In this cross-sectional study, interictal blood samples from n = 92 patients with episodic migraine (EM), n = 93 patients with chronic migraine (CM), and n = 42 healthy matched controls (HC) were studied. We assessed serum total-tau protein (t-tau) and for comparison neurofilament light chain protein (NfL), glial fibrillary acidic protein (GFAP), and ubiquitin carboxy-terminal hydrolase L (UCH-L1) concentrations using the Neurology 4-plex kit, on a single molecule array HD-X Analyzer (Quanterix Corp Lexington, MA). Matched serum/cerebrospinal fluid (CSF) samples were used for post-hoc evaluations of a central nervous system (CNS) source of relevant findings. We applied non-parametric tests to compare groups and assess correlations. Results Serum t-tau concentrations were elevated in EM [0.320 (0.204 to 0.466) pg/mL] and CM [0.304 (0.158 to 0.406) pg/mL] patients compared to HC [0.200 (0.114 to 0.288) pg/mL] (p = 0.002 vs. EM; p = 0.025 vs. CM). EM with aura [0.291 (0.184 to 0.486 pg/mL); p = 0.013] and EM without aura [0.332 (0.234 to 0.449) pg/mL; p = 0.008] patients had higher t-tau levels than HC but did not differ between each other. Subgroup analysis of CM with/without preventive treatment revealed elevated t-tau levels compared to HC only in the non-prevention group [0.322 (0.181 to 0.463) pg/mL; p = 0.009]. T-tau was elevated in serum (p = 0.028) but not in cerebrospinal fluid (p = 0.760). In contrast to t-tau, all proteins associated with cell damage (NfL, GFAP, and UCH-L1), did not differ between groups. Discussion Migraine is associated with t-tau elevation in serum but not in the CSF. Our clinical study identifies t-tau as a new target for migraine research.https://doi.org/10.1186/s10194-023-01663-5HeadacheCSFTrigeminal NerveMigraineTau protein |
| spellingShingle | Lucas Hendrik Overeem Bianca Raffaelli Robert Fleischmann Marie Süße Antje Vogelgesang Aleksandra Maleska Maceski Athina Papadopoulou Klemens Ruprecht Wendy Su Mirja Koch Anke Siebert Michal Arkuszewski Nadia Tenenbaum Jens Kuhle Uwe Reuter Serum tau protein elevation in migraine: a cross-sectional case–control study The Journal of Headache and Pain Headache CSF Trigeminal Nerve Migraine Tau protein |
| title | Serum tau protein elevation in migraine: a cross-sectional case–control study |
| title_full | Serum tau protein elevation in migraine: a cross-sectional case–control study |
| title_fullStr | Serum tau protein elevation in migraine: a cross-sectional case–control study |
| title_full_unstemmed | Serum tau protein elevation in migraine: a cross-sectional case–control study |
| title_short | Serum tau protein elevation in migraine: a cross-sectional case–control study |
| title_sort | serum tau protein elevation in migraine a cross sectional case control study |
| topic | Headache CSF Trigeminal Nerve Migraine Tau protein |
| url | https://doi.org/10.1186/s10194-023-01663-5 |
| work_keys_str_mv | AT lucashendrikovereem serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT biancaraffaelli serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT robertfleischmann serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT mariesuße serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT antjevogelgesang serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT aleksandramaleskamaceski serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT athinapapadopoulou serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT klemensruprecht serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT wendysu serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT mirjakoch serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT ankesiebert serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT michalarkuszewski serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT nadiatenenbaum serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT jenskuhle serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy AT uwereuter serumtauproteinelevationinmigraineacrosssectionalcasecontrolstudy |